Cargando…

Functional consequence of the MET-T1010I polymorphism in breast cancer

Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Shuying, Meric-Bernstam, Funda, Parinyanitikul, Napa, Wang, Bailiang, Eterovic, Agda K., Zheng, Xiaofeng, Gagea, Mihai, Chavez-MacGregor, Mariana, Ueno, Naoto T., Lei, Xiudong, Zhou, Wanding, Nair, Lakshmy, Tripathy, Debu, Brown, Powel H., Hortobagyi, Gabriel N., Chen, Ken, Mendelsohn, John, Mills, Gordon B., Gonzalez-Angulo, Ana M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413604/ https://www.ncbi.nlm.nih.gov/pubmed/25605252

Ejemplares similares

ClinSeK: a targeted variant characterization framework for clinical sequencing
por: Zhou, Wanding, et al.
Publicado: (2015)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Clinical outcomes based on multigene profiling in metastatic breast cancer patients
por: Basho, Reva K., et al.
Publicado: (2016)

Lactic acidosis, a potential toxicity from drug–drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report
por: Lagampan, Chalita, et al.
Publicado: (2021)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types
por: Chen, Tenghui, et al.
Publicado: (2016)

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019)

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2016)

10,10-Dimethylanthrone
por: Fun, Hoong-Kun, et al.
Publicado: (2010)

Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study
por: Kalapanida, Despoina, et al.
Publicado: (2019)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
por: Meric-Bernstam, Funda, et al.
Publicado: (2012)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Common Germline Risk Variants Impact Somatic Alterations and Clinical Features across Cancers
por: Namba, Shinichi, et al.
Publicado: (2023)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

Development and validation of a rapid psychosocial well-being screening tool in patients with metastatic breast cancer
por: Thanasansomboon, Bhumipat, et al.
Publicado: (2022)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

1010 ejercicios de defensa en fútbol
por: Vázquez Folgueira, Santiago
Publicado: (1995)

PReS-FINAL-1010: circulating micrornas in traps
por: Lucherini, OM, et al.
Publicado: (2013)

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
por: Xing, Yan, et al.
Publicado: (2019)

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
por: Masuda, Hiroko, et al.
Publicado: (2017)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
por: Gonzalez-Angulo, A M, et al.
Publicado: (2015)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Absence of ERK5/MAPK7 delays tumorigenesis in Atm(−/−) mice
por: Granados-Jaén, Alba, et al.
Publicado: (2016)

IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth
por: Ayars, Michael, et al.
Publicado: (2017)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

1010. Effective Management of HIV in Rural Georgia Using Telemedicine
por: Lawal, Folake J, et al.
Publicado: (2020)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
por: Palandri, F., et al.
Publicado: (2022)

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors
por: Liu, Qinghai, et al.
Publicado: (2009)

Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans
por: Brydon, Lena, et al.
Publicado: (2008)

Chronic Activation of Corticotropin-Releasing Factor Type 2 Receptors Reveals a Key Role for 5-HT1A Receptor Responsiveness in Mediating Behavioral and Serotonergic Responses to Stressful Challenge
por: Neufeld-Cohen, Adi, et al.
Publicado: (2012)

Hostility and Cellular Aging in Men from the Whitehall II Cohort
por: Brydon, Lena, et al.
Publicado: (2012)

Regulation of Bim in Health and Disease
por: Sionov, Ronit Vogt, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mdi92gek42kf838v5ai47j7ghq